Sat, Aug 30, 2014, 4:32 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Myriad Genetics Inc. Message Board

  • crelboyne crelboyne Apr 28, 2011 11:31 AM Flag

    Rules-Based Medicine

    Any thoughts on this acquisition? Looks like the market generally likes it.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I'm pretty much a fundamentals guy. Myriad got lucky with a product (BRACAnalysis) that they didn't have to lift a finger to sell in initially. Today's price is is fair based on the business they do with that one product. They have at least two more products that represent as large a market opportunity, but they need to be sold in. The company has neither experience nor staffing, but they know what they have to do. The complication is that they are obligated to devote substantial resources to the patent lawsuit. The route to a $60+ stock price seems to be within the abilities of 'ordinary good' management.

    • $22(gap fill).....Given the huge short interest,It's anybody's call how high she rips.next stop $24. This could turn into a monumental short squeeze. Iam not long for a squeeze(fundamentals instead).......but the trapped shorts are a huge catalyst that will drive us to much higher prices. I have seen this movie before & it doesn't end well for shorty. I flipped some at $22 bought back $21.70 avg. I can't help but trade a small piece for .25c gains.......entertains me as i wait for the real move.

    • spwra acquisition should help the solars short term. There could be a lot of consolidation in the industry. Out of my two holdings, TSL & JASO, I like TSL better though both are undervalued here. JASO's margins slipped a bit last Q although they should slip throughout the industry due to lower ASP's. Should get a nice bounce today and will hopefully lead to another long overdue uptrend. Have a good day.

    • Mygn's acquisition is very significant..........Big future growth driver with zero impact to earnings(cashflow neutral currently). A huge relationship builder with big pharma & their developement business. In a word(or four), Companion diagnostics game changer. Do some due diligence on "Rules based" & U will be highly impressed. This is another issue that will be clarified on the forthcoming earnings call A definite sentiment changer(to the positive. The acquisition coupled with increased earnings will drive short covering into the call. 306,000 shares traded thus far leaving nearly 7,000,000 to cover. Remember, there is no financing hedge built into the short interest. It's truly 7 million short! I don't want to jinx us but this could turn into a monumental short squeeze.................I hope so.

    • Myriad Genetics, Inc. - Common Stock
      Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover
      04/15/2011 6,951,227 0.17 650,345 10.69

 
MYGN
36.19+0.18(+0.50%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.